Business Wire

Semifinalist Teams Selected in $10M ANA Avatar XPRIZE Competition

5.4.2021 18:00:00 EEST | Business Wire | Press release

Share

XPRIZE, the world’s leader in designing and operating incentive competitions to solve humanity’s grand challenges, announced today that 38 teams from 16 countries are advancing to the semifinals round of the $10M ANA Avatar XPRIZE competition.

Sponsored by All Nippon Airways (ANA), Japan’s largest airline, the Avatar XPRIZE is a four-year global competition focused on the development of an avatar system that will deploy a human’s senses, actions, and presence to a remote location in real time, leading to a more connected world. These avatars must demonstrate the ability to execute tasks across a variety of real-world scenarios and convey a sense of presence for both the operator and the recipient in those interactions. In the future, avatars could help provide critical care and deploy immediate responses in emergency situations, or offer opportunities for exploration and new ways of collaboration, stretching the boundaries of what is possible and maximizing the impact of skill and knowledge sharing.

“We are rapidly approaching an era where it will be possible for a doctor in New York to export their skillset virtually to respond to a natural disaster across the globe,” said Anousheh Ansari, CEO of XPRIZE. “The task at hand for these incredible semifinalist teams competing in the ANA Avatar XPRIZE is to break through physical limitations and expand the capacity of humankind itself through transformative robotic avatar technology.”

In February 2021, qualified teams completed their semifinalist selection submissions—the second round of technical submissions for evaluation by the judging panel. Each team submitted a comprehensive write-up detailing their avatar system's capabilities and their development plans, accompanied by a demonstration video showcasing their technology in action. The judges extensively reviewed the submissions and selected 38 semifinalists to advance out of the field of 77 qualified teams.

The ANA Avatar XPRIZE semifinalist teams are:

  • 1to1Robotics, Hackensack, New Jersey, United States
  • Aham, Bangalore, India
  • Augnition, Helsinki, Finland
  • AvaDynamics, Pittsburgh, Pennsylvania, United States
  • Avatar Quest, San Jose, California, United States
  • AVATRINA, Urbana, Illinois, United States
  • BellContinuous, Arlington, Texas, United States
  • Cyberselves, Sheffield, United Kingdom
  • Dragon Tree Labs, Moscow, Russia
  • ENZO AVATAR, Bucaramanga, Colombia
  • Forged Droids, Tempe, Arizona, United States
  • GITAI, Tokyo, Japan
  • H2L, Tokyo, Japan
  • Human Fusions, Cleveland, Ohio, United States
  • i-Botics, Utrecht, Netherlands
  • iCub, Genoa, Italy
  • Inbiodroid, Irapuato, Mexico
  • Janus, Tsukuba, Japan
  • Junnichi Suko, Tokyo, Japan
  • Kimaera Dynamics, Toronto, Canada
  • Last Mile – small world project 2, Osaka, Japan
  • Limitless, Lugano, Switzerland
  • NimbRo, Bonn, Germany
  • Pollen Robotics, Bordeaux, France
  • proRobot, Vysoké Mýto, Czech Republic
  • Rezilient, St. Louis, Missouri, United States
  • Robot Guru (HoloSuit), Mysuru, India
  • Robotics Services LLC, Providence, Rhode Island, United States
  • Roboy, Munich, Germany
  • Sant'Anna, Pisa, Italy
  • SYNAPSE, Tokyo, Japan
  • Team Northeastern, Boston, Massachusetts, United States
  • Team SNU, Ulsan, South Korea
  • Team UNIST, Seoul, South Korea
  • Telexistence, Tokyo, Japan
  • Touchlab, Edinburgh, United Kingdom
  • Virtual Sapiens, Chennai, India
  • X-Presence, Kobe, Japan

Additional details about all competing teams can be found here.

“The breakthroughs that will develop out of the ANA Avatar XPRIZE have the potential to entirely reimagine the human experience,” said David Locke, Executive Prize Director of ANA Avatar XPRIZE. "We’re thrilled to announce the semifinalist teams and are excited to put their technologies to the test, and experience their ability to transport our sense of presence, during semifinals testing this fall.”

"Now that the semifinalist teams have been chosen, we are one very important step closer to realizing our dream of revolutionizing human connection," said Mitsuo Tomita, Senior Vice President of Marketing at All Nippon Airways. "As a company whose mission it is to connect people, we are beyond excited to see the technology that will be developed by these 38 teams. We are eager to see the innovative ways in which the teams will light up our imaginations with visions of a future in which travel and human connection are limitless."

After the completion of semifinals testing in Fall 2021, up to 20 teams will equally split a Semifinals prize purse of $2M and move on to finals testing in Summer 2022. There, they will compete to win a share of the $8M finals prize purse.

The grand prize will be awarded in June 2022 after finals testing, which will include performance tests based on specific tasks that showcase the application of avatar technologies across several use case scenarios. The winning team will integrate multiple emerging technologies to develop a physical, nonautonomous avatar system with which an operator can see, hear, and interact within a remote environment in a manner that feels as if they are truly there.

The ANA Avatar Advisory Board has been integral in the competition since its launch in January 2019. The group consists of esteemed robotics experts, haptics inventors, psychology professors, top entertainment researchers, virtual world creators, computer vision dynamos and more. The full list of experts can be found below with additional information and bios available here.

For more information on the ANA Avatar XPRIZE, the semifinalist teams, and ANA, please visit avatar.xprize.org.

About XPRIZE

XPRIZE, a 501(c)(3) nonprofit organization, is the global leader in designing and implementing innovative competition models to solve the world’s grandest challenges. Active competitions include the $100 Million XPRIZE Carbon Removal with Elon Musk, $20 Million NRG COSIA Carbon XPRIZE, $15 Million XPRIZE Feed the Next Billion, $10 Million XPRIZE Rainforest, $10 Million ANA Avatar XPRIZE, $5 Million IBM Watson AI XPRIZE, $5 Million XPRIZE Rapid Reskilling and $1M Digital Learning Challenge. For more information, visit xprize.org.

ABOUT ANA

Founded more than 60 years ago in 1952 with just two helicopters, All Nippon Airways (ANA), has become the largest airline in Japan, serving 46 international destinations and 50 domestic destinations.

ANA HOLDINGS Inc. (ANAHD) was established in 2013 as the largest airline group holding company in Japan comprised of 78 companies including ANA and Peach Aviation Limited, the leading LCC in Japan. The 78 companies organized under the ANAHD umbrella operate in a diverse range of markets, including air transportation, travel services and trade, and retail embody ANAHD’s shared values of exceptional service, responsible corporate citizenship and investment in the communities where they operate.

ANA is a launch customer and the biggest operator of the Boeing 787 Dreamliner, making ANAHD the biggest Dreamliner owner in the world. A member of Star Alliance since 1999, ANA has Joint Venture agreements with United Airlines, Lufthansa Airlines, Swiss International Airlines, Austrian Airlines and Brussels Airlines– giving it a truly global presence.

Supplementing its operations in commercial aviation, ANAHD has led the development of the innovative haptic robotics program, through its avatarin Inc. company, and its involvement in space with its partnership with JAXA, and other space related companies such as Astroscale and PD Aerospace.

The airline’s legacy of superior service has helped it earn SKYTRAX’s respected 5-Star rating every year since 2013, making ANA the only Japanese airline to win this prestigious designation and for eight consecutive years. ANA also has been recognized by Air Transport World as “Airline of the Year” three times (2007, 2013 and 2018); it is one of a select few airlines to win this prestigious award multiple times.

For more information, please refer to the following link:
https://www.ana.co.jp/group/en/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Caden Kinard, XPRIZE
caden.kinard@xprize.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye